J&J, Sid Mukher­jee's Vor team up to pair bis­pecifics with en­gi­neered stem cells for blood can­cer

J&J is one of many Big Phar­ma drug­mak­ers chas­ing the gold­en goose in on­col­o­gy bis­pecifics, with some ear­ly pos­i­tive re­sults in lung can­cer to show for it. Now, look­ing to break through in blood can­cer, J&J is pair­ing up with a pre­co­cious stem cell play­er to part­ner with its pipeline.

J&J’s Janssen unit has tapped Vor Bio­phar­ma, the brain­child of Co­lum­bia on­col­o­gist and best­selling au­thor Sid Mukher­jee, to pair the drug gi­ant’s bis­pe­cif­ic an­ti­bod­ies with Vor’s en­gi­neered stem cells in a mar­riage the com­pa­nies hope will change the game in treat­ing acute myeloid leukemia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER